NCORP Cancer Trials Activated - January 2019
Posted: January 18, 2019
The cancer studies below were approved recently and are open to enroll participants through the NCI Community Oncology Research Program (NCORP). NCORP is a national network that brings cancer clinical trials and cancer care delivery studies to people in their local communities.
For more information, click on the link in the title. All open NCORP studies are listed at: Find a Study.
Olanzapine with or without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III randomized, double blind, placebo controlled trial (A221602) was activated Oct. 15, 2018. Lead Research Base: Alliance. Summary: Study how well olanzapine with or without fosaprepitant works in preventing chemotherapy induced nausea and vomiting in cancer patients receiving chemotherapy that causes vomiting.
Testing Ramipril to Prevent Memory Loss in People with Glioblastoma (WF-1801) was activated Nov. 6, 2018. Lead Research Base: Wake Forest. Summary: Determine if an oral drug called Ramipril can lower the chance of memory loss in patients with glioblastoma getting chemoradiation.
Supportive Care Service Availability for Cancer Caregivers in Community Oncology Practices (WF-1803CD) was activated Dec. 10, 2018. Lead Research Base: Wake Forest. Summary: Understand current practices for engaging with informal (unpaid) caregivers of patients with cancer, characterize the availability of supportive care services, and assess the perspectives of multi-disciplinary oncology health care providers regarding identifying and supporting caregivers.